FDA expedites review of Chelsea's hypotension drug Northera

11/17/2011 | MedCityNews.com

The FDA gave priority-review status for Northera, Chelsea Therapeutics' drug candidate for neurogenic orthostatic hypotension, a condition associated with Parkinson's disease. The agency, which designated Northera an orphan medicine, is expected to decide on approval by March 28.

View Full Article in:

MedCityNews.com

Published in Brief: